Roche Cedes CEDIA DOA Reagents, Seals Corange Deal March 5
This article was originally published in The Gray Sheet
Executive Summary
Roche is negotiating with potential buyers of Boehringer Mannheim's Closed Enzyme Donor Immuno Assay (CEDIA) reagents for drugs-of-abuse (DOA) testing to comply with conditions of a Feb. 24 Federal Trade Commission settlement. The FTC settlement cleared the way for Roche's $10.2 bil. acquisition of Corange, the parent company of Boehringer Mannheim and DePuy.
You may also be interested in...
Roche Diagnostics Boosts Staff To Focus On Medical Genomics Research
Roche Diagnostics will bolster its genetic research efforts by adding a 100-person genomics staff as it seeks to capitalize on advances being made in the genomics field by shifting its R&D focus from clinical chemistry to molecular genetics.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.